Nigericin’s anticancer effects have been documented in several solid tumors, including lung, breast, and colorectal cancers, where it inhibits key signaling pathways such as Wnt/β-catenin, PI3K/Akt, and MAPK/ERK [22,36]. The gene discussed is AKT1; the disease is colorectal cancer.